[A controlled trial of prevention of recurrence of gastroduodenal ulcers with proxybarbital].
During 3 years, the usefulness of proxibarbal (Ipronal "Polfa") for gastro-duodenal ulcer recurrences prophylaxis has been studie in 62 patients in 7 clinics. A history of the gastro-duodenal ulcers, physical examinations, X-ray, and endoscopy consisted diagnostic and evaluation criteria. The drug was tested with double blind trial; 33 patients received proxibarbal in tablets of 50 mg and 29 persons received placebo tablets. Tested substances were administered for 3 years, six weeks every quarter, i.e. one tablet twice daily. No recurrences of the disease were seen in 20 out of 33 patients treated with proxibarbal and in 14 out of 29 patients receiving placebo. This result has not a statistical significance and so does not confirm the earlier report of Gamski and Tymiński on the usefulness of proxibarbal in the prevention of gastro-duodenal ulcer recurrences.
D000328:Adult; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010437:Peptic Ulcer / Q000188:drug therapy* / Q000517:prevention & control; D010919:Placebos; D012008:Recurrence; D014945:Wound Healing / Q000187:drug effects
D000897:Anti-Ulcer Agents; D010919:Placebos
Kontrolowana próba zapobiegania nawrotom choroby wrzodowej zoładka i dwunastnicy za pomoca proksybarbalu.